Remimazolam versus propofol for sedation in mechanically ventilated ICU patients: A systematic review and meta-analysis of randomized controlled trials.
Abstract
Background
Propofol is widely used for sedation in the intensive care unit (ICU), but its use may be limited by cardiovascular depression, hypertriglyceridemia, and propofol infusion syndrome. Remimazolam has emerged as a potential alternative to propofol, with rapid metabolism, predictable recovery, and flumazenil reversibility. However, evidence regarding its use in mechanically ventilated ICU patients remains limited.
Methods
PubMed, Embase, Cochrane, and ClinicalTrial.gov databases were reviewed for randomized controlled trials (RCTs) comparing remimazolam with propofol in mechanically ventilated ICU patients. The primary outcome was percentage of time within the target sedation range. Secondary outcomes included sedation success rate, 28-day mortality, ICU mortality, length of ICU stay, and duration of mechanical ventilation. Safety outcomes including adverse events leading to dose reduction, hypotension, and delirium were evaluated. Continuous endpoints were reported using mean differences (MDs), and dichotomous outcomes were analyzed using risk ratios (RRs), with 95% confidence intervals (CIs).
Results
Six RCTs including 705 patients were analyzed. No statistically significant difference was detected in the percentage of time within the target sedation range (MD, -0.45%; 95% CI, -2.46 to 1.55; p = 0.56; I2 = 0%). No significant differences were detected in sedation success rate, 28-day mortality, ICU mortality, ICU length of stay, and duration of mechanical ventilation, or safety outcomes, although several estimates were imprecise.
Conclusion
Remimazolam probably results in little to no difference in sedation efficacy compared with propofol in mechanically ventilated ICU patients. However, uncertainty remains regarding clinical and safety outcomes. Larger multinational RCTs are warranted to clarify these effects.